AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33433318 — intervention group
Group type: COMPARATOR
Intervention: Sodium ferric gluconate 125 mg weekly
Number of subjects: 173
Study 36171282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (ICA)
Number of subjects: 68
Study 36171282 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (ECA)
Number of subjects: 68
Study 32151220 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (200 g/L glucose, 66.7 U/L insulin, and 80 mmol/L KCl) administered intravenously at 1 mL/kg per hour 10 minutes before anesthesia and continuously for 12.5 hours
Number of subjects: 930
Study 32151220 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 930
Study 34177805 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle modification protocol (YLP) for 9 consecutive days, followed by daily home and weekly supervised practices for 3 months.
Number of subjects: 3380
Study 34177805 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle modification protocol (YLP)
Number of subjects: 3380
Study 34177805 — intervention group
Group type: COMPARATOR
Intervention: Standard of care advice for diabetes prevention
Number of subjects: 3380
Study 32568616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense V-Network algorithm
Number of subjects: 100
Study 34823258 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe
Number of subjects: 1076
Study 34823258 — intervention group
Group type: EXPERIMENTAL
Intervention: CAQ
Number of subjects: 1076
Study 32990570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve bioprosthesis
Number of subjects: 355
Study 32990570 — intervention group
Group type: COMPARATOR
Intervention: Mechanical prosthesis
Number of subjects: 355
Study 36127888 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt‐1 levels in patients with placenta accreta spectrum disorder
Number of subjects: 80
Study 36127888 — intervention group
Group type: COMPARATOR
Intervention: sFlt‐1 levels in patients with normal pregnancies (control group)
Number of subjects: 80
Study 32715401 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (intravenous tranexamic acid)
Number of subjects: 100
Study 32715401 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 100
Study 32049887 — intervention group
Group type: EXPERIMENTAL
Intervention: VL20
Number of subjects: 64
Study 32049887 — intervention group
Group type: EXPERIMENTAL
Intervention: VL40
Number of subjects: 64
Study 32049887 — intervention group
Group type: COMPARATOR
Intervention: VL0
Number of subjects: 64
Study 32049887 — intervention group
Group type: COMPARATOR
Intervention: VL10
Number of subjects: 64
Study 35088469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 63
Study 35088469 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 63
Study 35088469 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 63
Study 34344638 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐VMP
Number of subjects: 706
Study 34344638 — intervention group
Group type: COMPARATOR
Intervention: VMP
Number of subjects: 706
Study 35130487 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dose priming regimen (days 1, 8, and 29) with 9 × 10^5 PfSPZ/dose
Number of subjects: 84
Study 35130487 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dose priming regimens (days 1, 3, 5, 7, and 113; days 1, 3, 5, and 7; days 1, 3, 5, 7, and 29)
Number of subjects: 84
Study 35130487 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 84
Study 34157056 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Contact Self‐Efficacy Scale for Third Agers (SET)
Number of subjects: 1139
Study 35356927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 35356927 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant chemotherapy)
Number of subjects: 0
Study 33069172 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 1632
Study 33069172 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering
Number of subjects: 1632
Study 32600394 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz/1200 pulses/8 trains/90% resting motor threshold) delivered over the right DLPFC for 5 consecutive days/week for 4 weeks
Number of subjects: 90
Study 32600394 — intervention group
Group type: COMPARATOR
Intervention: Sham‐rTMS
Number of subjects: 90
Study 35076087 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 35076087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35076087 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (2 pills)
Number of subjects: 0
Study 35076087 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (1 pill)
Number of subjects: 0
Study 33386756 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC
Number of subjects: 30
Study 33386756 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg THC
Number of subjects: 30
Study 33386756 — intervention group
Group type: COMPARATOR
Intervention: THC blood concentration
Number of subjects: 30
Study 35568049 — intervention group
Group type: EXPERIMENTAL
Intervention: WEVEE VLP vaccine (6 μg, 30 μg, or 60 μg) with or without aluminium hydroxide suspension (alum) adjuvant, administered by intramuscular injection at study day 0 and week 8.
Number of subjects: 30
Study 35568049 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg plus alum group
Number of subjects: 30
Study 35568049 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of WEVEE VLP vaccine
Number of subjects: 30
Study 34301652 — intervention group
Group type: EXPERIMENTAL
Intervention: FCal-POCT (point-of-care testing for faecal calprotectin) after online training
Number of subjects: 406
Study 34301652 — intervention group
Group type: COMPARATOR
Intervention: Dutch GP guidelines (control group)
Number of subjects: 406
Study 34301652 — intervention group
Group type: EXPERIMENTAL
Intervention: FCal-POCT
Number of subjects: 406
Study 32700421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 0
Study 32700421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 0
Study 32700421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32700421 — intervention group
Group type: COMPARATOR
Intervention: Non-ertugliflozin
Number of subjects: 0
Study 34839481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (1,000 mg dose of low-molecular weight iron dextran over one hour)
Number of subjects: 23
Study 34839481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 23
Study 34839481 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 23
Study 34839481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IV iron and oral iron)
Number of subjects: 23
Study 33563257 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel releasing intrauterine system (LNG-IUS)
Number of subjects: 201
Study 33542371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cionni modified capsular tension rings (MCTR) during lens subluxation surgery
Number of subjects: 66
Study 32421159 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) with standard medical care
Number of subjects: 67
Study 32421159 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care only (control group)
Number of subjects: 67
Study 35149625 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 80
Study 35149625 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson relaxation technique
Number of subjects: 80
Study 35149625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 33292982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot conditions (42.3 ± 0.3 °C; 28.4 ± 5.2% Rh)
Number of subjects: 22
Study 33292982 — intervention group
Group type: COMPARATOR
Intervention: Cool conditions (24.0 ± 0.0 °C; 14.4 ± 3.4% Rh)
Number of subjects: 22
Study 36079884 — intervention group
Group type: EXPERIMENTAL
Intervention: 6AA (12 g of non‐essential amino acid formulation orally, 4 g three times a day)
Number of subjects: 50
Study 36079884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent doses to 6AA)
Number of subjects: 50
Study 33452595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (twice daily for 16 weeks)
Number of subjects: 190
Study 32145287 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable stents (slow, medium, fast degradation)
Number of subjects: 38
Study 32145287 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable stents
Number of subjects: 38
Study 34000894 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute use of smartphone social network apps
Number of subjects: 16
Study 34000894 — intervention group
Group type: COMPARATOR
Intervention: Watching a documentary
Number of subjects: 16
Study 32217045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV)
Number of subjects: 22
Study 32217045 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristic curve for icIVC
Number of subjects: 22
Study 32217045 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristic curve for idIVC
Number of subjects: 22
Study 33994179 — intervention group
Group type: COMPARATOR
Intervention: Custom-made foot orthosis
Number of subjects: 27
Study 33994179 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated foot orthosis
Number of subjects: 27
Study 33126825 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 42
Study 33126825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 34922061 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins (320 mg daily for 12 weeks)
Number of subjects: 0
Study 34922061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy 20-60 mg/d
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy 80-120 mg/d
Number of subjects: 161
Study 34127089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy 20-120 mg/d + Li/VPA
Number of subjects: 161
Study 34127089 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Li/VPA
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (long-term)
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lurasidone therapy (long-term)
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (pediatric)
Number of subjects: 161
Study 34127089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pediatric)
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (pediatric)
Number of subjects: 161
Study 34127089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (pediatric long-term)
Number of subjects: 161
Study 35847029 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinzhen Oral Liquid (JZOL) and Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution (AHCHOS) placebo
Number of subjects: 1000
Study 35847029 — intervention group
Group type: COMPARATOR
Intervention: AHCHOS and JZOL placebo
Number of subjects: 1000
Study 32963028 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (dexamethasone)
Number of subjects: 0
Study 32963028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36469833 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DHAP (rituximab plus dexamethasone, high-dose cytarabine, and cisplatin)
Number of subjects: 0
Study 36469833 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0
Study 36469833 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DHAP
Number of subjects: 0
Study 36469833 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 0
Study 33481813 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg daily)
Number of subjects: 80
Study 33481813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33481813 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 80
Study 32718308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for reduction in drinking
Number of subjects: 20
Study 34524652 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater than one’s usual negative affect and shape/weight-related cognitions
Number of subjects: 25
Study 34524652 — intervention group
Group type: EXPERIMENTAL
Intervention: Spending time on social media
Number of subjects: 25
Study 34524652 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending social events
Number of subjects: 25
Study 33931884 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg (Part B)
Number of subjects: 20
Study 33931884 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg (Part B)
Number of subjects: 20
Study 33931884 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg (Part C)
Number of subjects: 20
Study 33931884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Part B)
Number of subjects: 20
Study 32381158 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 22655
Study 32381158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22655
Study 32381158 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved LDL-C <20 mg/dl
Number of subjects: 22655
Study 32381158 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved LDL-C ≥100 mg/dl
Number of subjects: 22655
Study 35976578 — intervention group
Group type: EXPERIMENTAL
Intervention: NOL-guided fentanyl dosing (NOL)
Number of subjects: 75
Study 35976578 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SOC)
Number of subjects: 75
Study 33881715 — intervention group
Group type: EXPERIMENTAL
Intervention: YYHG high-dose
Number of subjects: 288
Study 33881715 — intervention group
Group type: EXPERIMENTAL
Intervention: YYHG low-dose
Number of subjects: 288
Study 33881715 — intervention group
Group type: COMPARATOR
Intervention: Positive control (XSTG)
Number of subjects: 288
Study 33881715 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 288
Study 33881715 — intervention group
Group type: EXPERIMENTAL
Intervention: YYHG treatment
Number of subjects: 288
Study 32282021 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 484
Study 32282021 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 484
Study 32282021 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers (MPO-ANCA-positive disease)
Number of subjects: 484
Study 32282021 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (MPO-ANCA-positive disease)
Number of subjects: 484
Study 32282021 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers (PR3-ANCA-positive AAV)
Number of subjects: 484
Study 32282021 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (PR3-ANCA-positive AAV)
Number of subjects: 484
Study 32207836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naloxone co-administration with ticagrelor and morphine
Number of subjects: 0
Study 35141806 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 13
Study 35141806 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF + DPSC
Number of subjects: 13
Study 32883493 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Number of subjects: 2258
Study 32883493 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasectomy (liver metastasis only)
Number of subjects: 2258
Study 33270047 — intervention group
Group type: EXPERIMENTAL
Intervention: UV photofunctionalization
Number of subjects: 17
Study 33270047 — intervention group
Group type: COMPARATOR
Intervention: Untreated miniscrews (Control)
Number of subjects: 17
Study 35635850 — intervention group
Group type: EXPERIMENTAL
Intervention: RobotReviewer-assisted RoB assessments
Number of subjects: 145
Study 35635850 — intervention group
Group type: COMPARATOR
Intervention: Control group (human effort only)
Number of subjects: 145
Study 34226985 — intervention group
Group type: EXPERIMENTAL
Intervention: PROERD intervention (10 classes conducted by trained police officers)
Number of subjects: 4030
Study 32228267 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on age >52, WBC >10 × 10^9/L, PLT ≤10 × 10^9/L, LDH >500 U/L
Number of subjects: 570
Study 33742307 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive paid at testing
Number of subjects: 0
Study 33742307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33742307 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 0
Study 33742307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge
Number of subjects: 0
Study 32990365 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrowroot kefir flour (24 hr of fermentation; AKF1)
Number of subjects: 6
Study 32990365 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrowroot kefir flour (48 hr of fermentation; AKF2)
Number of subjects: 6
Study 32990365 — intervention group
Group type: COMPARATOR
Intervention: Control flour (CF)
Number of subjects: 6
Study 34324700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8)
Number of subjects: 571
Study 34324700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline and placebo at weeks 4 and 8)
Number of subjects: 571
Study 34324700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 34324700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly
Number of subjects: 571
Study 34324700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly
Number of subjects: 571
Study 33201236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall-prevention tool kit
Number of subjects: 37231
Study 34083627 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (DAPT)
Number of subjects: 2083
Study 34083627 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 2083
Study 33022991 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-based Low Carbohydrate Diet (a‐LCD)
Number of subjects: 45
Study 33022991 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 45
Study 35418427 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day) for 3 days
Number of subjects: 570
Study 35418427 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (2000 IU/day + standard dose 400 IU/day) for 1 year
Number of subjects: 570
Study 34808749 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy (RSWT) in the lateral elbow area plus scapular back area
Number of subjects: 54
Study 34808749 — intervention group
Group type: COMPARATOR
Intervention: Radial shock wave therapy (RSWT) only in the lateral elbow area
Number of subjects: 54
Study 32093769 — intervention group
Group type: EXPERIMENTAL
Intervention: JOURNEY II Bi-Cruciate Stabilised knee arthroplasty
Number of subjects: 80
Study 32093769 — intervention group
Group type: COMPARATOR
Intervention: GENESIS II total knee arthroplasty
Number of subjects: 80
Study 35172198 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg daily
Number of subjects: 4401
Study 35172198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 34346563 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-gene signature
Number of subjects: 0
Study 34346563 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-gene signature combined with TNM stage and age
Number of subjects: 0
Study 32275362 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion at fanwei point, 40 min each time, once a day for 5 times a week for 6 weeks
Number of subjects: 134
Study 32275362 — intervention group
Group type: COMPARATOR
Intervention: Itopride hydrochloride tablets, 50 mg each time, three times a day for 6 weeks
Number of subjects: 134
Study 34496174 — intervention group
Group type: COMPARATOR
Intervention: Iron syrup
Number of subjects: 3300
Study 34496174 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrient powders
Number of subjects: 3300
Study 34496174 — intervention group
Group type: COMPARATOR
Intervention: Iron syrup and multiple micronutrient powders
Number of subjects: 3300
Study 34496174 — intervention group
Group type: COMPARATOR
Intervention: Iron syrup, multiple micronutrient powders, and placebo
Number of subjects: 3300
Study 32160310 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic-based software tools
Number of subjects: 50
Study 32160310 — intervention group
Group type: COMPARATOR
Intervention: Commercial vendor-based software tools
Number of subjects: 50
Study 32160310 — intervention group
Group type: EXPERIMENTAL
Intervention: All software investigated
Number of subjects: 50
Study 32160310 — intervention group
Group type: EXPERIMENTAL
Intervention: All software tools
Number of subjects: 50
Study 32160310 — intervention group
Group type: EXPERIMENTAL
Intervention: All software tools with quality assurance (QA)
Number of subjects: 50
Study 32160310 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic-based groups
Number of subjects: 50
Study 32160310 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial vendors
Number of subjects: 50
Study 36104745 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (75 mg twice per day) + placebo
Number of subjects: 46